Sanofi released its annual drug-price increase report just days before CEO Olivier Brandicourt–alongside other biopharma chiefs–was to testify before the Senate Finance Committee. The bottom line: Its average U.S. list prices increased 4.6% in 2018. However, that increase was offset by rebates, resulting in a net decline of 8%. Find out what the report had to say about its insulin pricing rationale, including for the new Admelog (insulin lispro) and Toujeo (insulin glargine). See how Sanofi is responding to outrage over high drug prices, and learn about its investment in patient-assistance programs.